1641P Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects

Journal article

Peer reviewed

C. Kyriakopoulos, G. Chatta, A.L. Laccetti, N. Iannotti, A.O. Sokolova, S.J. Hotte, R. Tutrone, M.C. Markowski, L.T. Nordquist, R. Pili, …

Annals of oncology, Vol.35, pp.S990-S990

09/2024

Files and links (1)

url

https://doi.org/10.1016/j.annonc.2024.08.1722View

Published (Version of record) Open

1 Record Views

Title: 1641P Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Creators: C. Kyriakopoulos - University of Wisconsin Carbone Cancer Center
G. Chatta - Roswell Park Comprehensive Cancer Center
A.L. Laccetti - Memorial Sloan Kettering Cancer Center
N. Iannotti - Hematology Oncology Associates
A.O. Sokolova - Oregon Health & Science University
S.J. Hotte - Juravinski Cancer Centre
R. Tutrone - Carolina Urologic Research Center
M.C. Markowski - Sidney Kimmel Cancer Center
L.T. Nordquist - Urology Cancer Center and GU Research Network
R. Pili - University at Buffalo, State University of New York
F. Saad - Centre Hospitalier de l’Université de Montréal
J. Zhang - Moffitt Cancer Center
K. Villaluna - Essa Pharma (United States)
B. Younginger - Essa Pharma (United States)
R. Le Moigne - Essa Pharma (United States)
A. Cesano - Essa Pharma (United States)
Publication Details: Annals of oncology, Vol.35, pp.S990-S990
Publisher: Elsevier Ltd
Identifiers: 991006262529102656
Academic Unit: Radiology
Language: English
Resource Type: Journal article